Actavis plc, of Dublin, extended the expiration date of its offer to guarantee the outstanding debt securities of Forest Laboratories Inc., of New York, in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities. The consent solicitations were originally scheduled to expire at 5 p.m., EDT, on June 6, 2014. The expiration date has been extended until the same hour on June 12, 2014.

Teva Pharmaceutical Industries Ltd., of Jerusalem, said the FDA has expanded the indication for Azilect (rasagiline tablets) from monotherapy and adjunct to levodopa to now include adjunct to dopamine agonists. The new indication reflects that Azilect can be used alone or in combination with other Parkinson's disease medications. The approval reinforces the growing clinical evidence demonstrating the benefit of Azilect across all stages of the illness, Teva said.

Valeant Pharmaceuticals International Inc., of Laval, Quebec, received notice that the FDA has approved the new drug application for Jublia (efinaconazole 10 percent topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.